Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis.

Article Details

Citation
Copy to clipboard

Bouazza N, Pestre V, Jullien V, Curis E, Urien S, Salmon D, Treluyer JM

Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis.

Br J Clin Pharmacol. 2012 Dec;74(6):971-7. doi: 10.1111/j.1365-2125.2012.04292.x.

PubMed ID
22486719 [ View in PubMed
]
Abstract

AIMS: This study was performed to describe clindamycin, administered either orally or intravenously, concentration-time courses to patients with osteomyelitis, to study the effects of different covariates on clindamycin pharmacokinetics and to simulate an optimized administration scheme. METHODS: Clindamycin concentrations were measured in 50 patients. A total of 122 plasma concentrations were available (58 from oral administration and 64 from i.v. infusion). A population pharmacokinetic model was developed with MONOLIX 4 software. RESULTS: A one compartment model adequately described the data. Clindamycin clearance increased significantly with body weight (BW). The typical population estimates (interindividual variability) for clearance, volume of distribution and absorption rate constant were 16.2 l h(-1) (0.39), 70.2 l and 0.92 h(-1) , respectively. The bioavailability of the oral form was estimated to be 87.6%. According to BW, theoretical doses needed to reach a C(min) of 2 mg l(-1) were then calculated. CONCLUSIONS: The current recommendation of 600 mg three times daily seems to be effective up to 75 kg but the dose should be raised to 900 mg three times daily thereafter. These assumptions should be prospectively confirmed.

DrugBank Data that Cites this Article

Drugs